Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Rigel Pharmaceuticals (RIGL) stock in plain English

Free brief · no signupStart here
RIGLPublished Nov 13, 2026
Rigel Pharmaceuticals
Healthcare · Biotechnology
Markets targeted prescription therapies for hematologic cancers and autoimmune conditions. Sells directly to specialty pharmacies and licenses global rights to overseas healthcare partners.
Assets:
Tavalisse oral therapyapproved prescription treatment for chronic immune thrombocytopenia
South San Francisco campusdedicated research laboratories and corporate headquarters
Rezlidhia commercial linetargeted prescription capsule for relapsed acute myeloid leukemia
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

80
OPS ScoreOperating finances
Latest quote
-3.15%$41.19
$775.61M
2.7×
$288.33M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 13, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was RIGL. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Rigel Pharmaceuticals (RIGL) do?

Rigel Pharmaceuticals (RIGL) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Markets targeted prescription therapies for hematologic cancers and autoimmune conditions. Sells directly to specialty pharmacies and licenses global rights to overseas healthcare partners. Develops and sells oral targeted therapies for rare blood cancers and immune disorders through specialty pharmacies. It is worth $775.61M on the market and sold $288.33M over the last year.

Market cap
$775.61M
P/E ratio
2.7×
Annual sales
$288.33M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 13, 2026

Brands and businesses behind RIGL

  • Tavalisse: Generates revenue as a prescription oral tablet for adult patients with chronic immune thrombocytopenia.
  • Rezlidhia: Earns sales as a daily oral capsule treating specific mutated forms of acute myeloid leukemia.
  • Gavreto: Produces revenue as an oral kinase inhibitor for adults with specific RET-altered lung and thyroid cancers.

RIGL’s flags, in plain English

Each flag is a number from Rigel Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.

Low debt

Low debt, only 2% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 89.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Capital Works Hard

Earns 69% a year on the money it invests in the business. The money in the business, from shareholders and lenders together, earns a strong return. That points to a company that picks its investments well.

Profit with Caveats

Bottom-line profit of $307M in the 12 months to Sep 30, 2026, next to $76M of profit from the business. Bottom-line profit is well above what the business itself earned. The difference came from outside day-to-day operations, such as an investment gain, a tax benefit, the sale of a business or interest on its cash. Some of these may not repeat, and they make the P/E look lower than the business alone would.

2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about RIGL

How big is Rigel Pharmaceuticals?

Rigel Pharmaceuticals’ market cap is $775.61M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $288.33M: what customers paid the company over the last year, before any costs.

What is RIGL’s P/E ratio?

RIGL’s P/E ratio is 2.7×. Investors pay about 2.7 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with RIGL?

A significant share of annual revenue depends on prescription sales from a single drug for immune thrombocytopenia. That is one risk on Rigel Pharmaceuticals’ card. Its first risk flag is Profit with Caveats, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Rigel Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. RIGL’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card